The company holds a Beta of 0.0, which implies not very significant fluctuations relative to the market. the returns on MARKET and PhaseRx are completely uncorrelated.
Risk-Adjusted Performance
Weakest
Weak
Strong
Over the last 90 days PhaseRx has generated negative risk-adjusted returns adding no value to investors with long positions. Even with relatively invariable basic indicators, PhaseRx is not utilizing all of its potentials. The latest stock price agitation, may contribute to short-term losses for the retail investors. ...more
PhaseRx
PhaseRx Relative Risk vs. Return Landscape
If you would invest 0.01 in PhaseRx on November 7, 2025 and sell it today you would earn a total of 0.00 from holding PhaseRx or generate 0.0% return on investment over 90 days. PhaseRx is currently producing negative expected returns and takes up 0.0% volatility of returns over 90 trading days. Put another way, 0% of traded pink sheets are less volatile than PhaseRx, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days.
Expected Return
Risk
PhaseRx Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of PhaseRx for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for PhaseRx can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
PhaseRx generated a negative expected return over the last 90 days
PhaseRx has some characteristics of a very speculative penny stock
PhaseRx has high likelihood to experience some financial distress in the next 2 years
Net Loss for the year was (20.14 M) with profit before overhead, payroll, taxes, and interest of 0.
PhaseRx has accumulated about 5.26 M in cash with (9.81 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.45, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
PhaseRx Fundamentals Growth
PhaseRx Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of PhaseRx, and PhaseRx fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on PhaseRx Pink Sheet performance.
Assessing PhaseRx's fundamental ratios provides investors with valuable insights into PhaseRx's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the PhaseRx is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
PhaseRx, Inc., a biopharmaceutical company, engages in developing a portfolio of products for the treatment of inherited enzyme deficiencies in the liver using intracellular enzyme replacement therapy. The company was incorporated in 2006 and is headquartered in Seattle, Washington. Phaserx operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 10 people.
Things to note about PhaseRx performance evaluation
Checking the ongoing alerts about PhaseRx for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for PhaseRx help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
PhaseRx generated a negative expected return over the last 90 days
PhaseRx has some characteristics of a very speculative penny stock
PhaseRx has high likelihood to experience some financial distress in the next 2 years
Net Loss for the year was (20.14 M) with profit before overhead, payroll, taxes, and interest of 0.
PhaseRx has accumulated about 5.26 M in cash with (9.81 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.45, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Evaluating PhaseRx's performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate PhaseRx's pink sheet performance include:
Analyzing PhaseRx's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether PhaseRx's stock is overvalued or undervalued compared to its peers.
Examining PhaseRx's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
Evaluating PhaseRx's management team can have a significant impact on its success or failure. Reviewing the track record and experience of PhaseRx's management team can help you assess the Company's leadership.
Pay attention to analyst opinions and ratings of PhaseRx's pink sheet. These opinions can provide insight into PhaseRx's potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating PhaseRx's pink sheet performance is not an exact science, and many factors can impact PhaseRx's pink sheet market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.
Additional Tools for PhaseRx Pink Sheet Analysis
When running PhaseRx's price analysis, check to measure PhaseRx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PhaseRx is operating at the current time. Most of PhaseRx's value examination focuses on studying past and present price action to predict the probability of PhaseRx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PhaseRx's price. Additionally, you may evaluate how the addition of PhaseRx to your portfolios can decrease your overall portfolio volatility.